The University of Medicine & Dentistry of New Jersey together with the company screened the around 30 patients for the inclusion or exclusion in the study.
Proteonomix chief executive officer Michael Cohen said so far 30 patients have been screened based on the inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol.
"The initiation of screening is the first step towards commencement of the clinical trial of UMK-121," Cohen added.